ShareSoc Growth Company Seminar (IN-PERSON EVENT), London 5 November 2026, 5:30pm
Featuring: Bioventix (BVXP), Odyssean Investment Trust plc (OIT), Third Company to be announced soon
Location: ISH Venues
229 Great Portland Street
W1W 5PN
Companies presenting
Bioventix (BVXP)
Bioventix creates, manufactures and supplies high affinity sheep monoclonal antibodies (SMAs) for use in diagnostic applications. Bioventix antibodies are preferred for use when they confer an improved test performance compared to other available antibodies.
Most of Bioventix’s antibodies are used on blood-testing machines installed in hospitals and other laboratories around the world. Bioventix makes antibodies using its SMA technology for supply to diagnostic companies for subsequent manufacture into reagent packs used on blood-testing machines. These blood-testing machines are supplied by large multinational in vitro diagnostics (IVD) companies such as Roche Diagnostics, Siemens Healthineers, Abbott Diagnostics & Beckman Coulter. Antibody-based blood tests are used to help diagnose many different conditions including, amongst others, heart disease, thyroid function, fertility, infectious disease and cancer.
Presenter:
Peter Harrison – CEO
Peter is 66 years old and has over 30 years’ experience of antibody technology at Celltech, KS Biomedix & Bioventix.
Odyssean Investment Trust plc (OIT)
Odyssean Investment Trust is a UK investment company whose shares are traded on the London Stock Exchange. Its investment objective is to achieve attractive total returns per share principally through capital growth over a longer-term period.
It has been managed since its 2018 IPO by Odyssean Capital LLP, an award-winning boutique fund manager, which focuses on investing in smaller quoted companies. OIT’s investment strategy is to manage a concentrated portfolio of small- and mid-cap companies that the Portfolio Manager identifies as undervalued, where it has identified scope for “self-help” to drive shareholder returns. The Portfolio Manager takes an engaged, long-term ownership approach to support portfolio companies to undertake strategic, operational, and/or governance improvements.
Presenter:
Edward Wielechowski, Partner
Edward is a Fund Manager at Odyssean Capital LLP in London, where he has worked since December 2017. He focuses on investing in small to mid-sized companies across both public and private markets, bringing a private equity philosophy to public market investments. As portfolio manager for the Odyssean Investment Trust, he co-manages a concentrated portfolio of well-researched UK smaller companies, typically outside the FTSE 250, aiming to deliver 15% annualised returns over five years by targeting businesses with transformation potential trading below intrinsic value. His approach emphasises mid- to long-term holding, quality assessment, and disciplined focus on £100m–£1bn market cap companies, differentiating from pure growth or value strategies.
Third Company – to be announced soon
This seminar consists of a 20-minute presentation by each company followed by 10 minutes of questions and answers. After the presentations there will be an hour of networking with light buffet and wine where you will have the opportunity to engage directly with company directors and share your investing experience with fellow investors.
Event registration opens at 5.00 pm and presentations commence at 5.30 pm.
Places are limited and will be allocated on a first come, first served basis.
Stockopedia will provide facts and figures on the presenting companies for attendees (don’t forget that ShareSoc subscribing members can get a special discount on Stockopedia subscription rates – see Member Offers).
Registration
Exclusive to Full ShareSoc and Combined (ShareSoc & SIGnet) members
To register, members should log in, then just click “SUBMIT” below.
Click here for help on logging in or email events@sharesoc.org
If you want to upgrade, please click here.